Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1 091,51
-2,30
-0,21%
—1 093,811 096,521 100,221 091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1 237,98
-16,83
-1,34%
—1 254,811 253,011 253,871 226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1 744,71
-16,40
-0,93%
—1 761,111 764,271 766,881 744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3 260,69
+48,86
+1,52%
—3 211,833 227,213 268,383 226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1 466,80
-7,72
-0,52%
—1 474,521 479,031 481,041 466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2 397,50
+5,38
+0,22%
—2 392,122 396,952 421,222 382,32——
Q1 2026 earnings • in 2 days
See details
NBIX:NASDAQ
Neurocrine Biosciences Inc
USD 131,78
+0,08%
(+0,11) 1D
USD 131,78
0,00% (0,00)
After hours
Closed: 1 Mei, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NBIX...
Open
USD 131,79
High
USD 132,41
Low
USD 129,86
Mkt. cap
13,25 mjd
Avg. vol.
1,08 m
Volume
680,08 k
P/E ratio
28,22
52-wk high
USD 160,18
52-wk low
USD 101,15
EPS
USD 4,67
Beta
0,35
Shares outstanding
100,36 m
No. of employees
2 k
News stories
From sources across the web
Profile
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
About Neurocrine Biosciences Inc
CEOKevin C. Gorman
Employees2 k
Founded1992
HeadquartersSan Diego, Kalifornië, Verenigde State van Amerika
Sector-
Websiteneurocrine.com
Next call oor 2 dae
Di. 5 Mei, 16:30
Fiscal Period
Q1 2026
Normalized EPS / Estimate
-/ (1,70 est.)USD
Revenue / Estimate
-/ (767,88 m est.)USD
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earningsInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mrt. 2025
Jun. 2025
Sep. 2025
Des. 2025
Revenue
572,60 m
687,50 m
794,90 m
805,50 m
Cost of goods sold
272,40 m
255,60 m
264,00 m
275,80 m
Cost of revenue
272,40 m
255,60 m
264,00 m
275,80 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
276,50 m
286,30 m
291,60 m
302,50 m
Operating expense
276,50 m
286,30 m
291,60 m
302,50 m
Total operating expenses
548,90 m
541,90 m
555,60 m
578,30 m
Operating income
23,70 m
145,60 m
239,30 m
227,20 m
Other non operating income
-
-
-
-
EBT including unusual items
14,70 m
159,50 m
291,80 m
239,40 m
EBT excluding unusual items
45,40 m
166,20 m
261,50 m
253,00 m
Income tax expense
6,80 m
52,00 m
82,30 m
85,70 m
Effective tax rate
46,26%
32,60%
28,20%
35,80%
Other operating expenses
-
-
-
-
Net income
7,90 m
107,50 m
209,50 m
153,70 m
Net profit margin
1,38%
15,64%
26,36%
19,08%
Earnings per share
0,70
1,65
2,17
1,88
Interest and investment income
21,70 m
20,60 m
22,20 m
25,80 m
Interest expense
-
-
-
-
Net interest expenses
21,70 m
20,60 m
22,20 m
25,80 m
Depreciation and amortization charges
-
-
-
-
EBITDA
31,30 m
152,90 m
247,00 m
234,70 m
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer